Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Gasparini, Pierluigi ^a   Fassan, Matteo ^a,b   Cascione, Luciano ^a   Guler, Gulnur ^c   Balci, Serdar ^c   Irkkan, Cigdem ^c   Paisie, Carolyn ^a   Lovat, Francesca ^a   Morrison, Carl ^d   Zhang, Jianying ^e   Scarpa, Aldo ^b   Croce, Carlo M ^a   Shapiro, Charles L ^e   Huebner, Kay ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b UNIVERSITY AND HOSPITAL TRUST OF VERONA   (Italy)

^c HACETTEPE UNIVERSITY   (Turkey)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; MESSENGER RNA; TUMOR MARKER;

ADULT; AFRICAN AMERICAN; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CDK6 GENE; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; HER4 GENE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; OVERALL SURVIVAL; PRIMARY TUMOR; PROTEIN EXPRESSION; RACISM; TNFSF10 GENE; TRIPLE NEGATIVE BREAST CANCER; TUMOR GENE;

ADULT; AGED; BREAST; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS; RECEPTORS, ANDROGEN; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84895525356     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088525     Document Type: Article

References (47)

1. Moe RE, Anderson BO (2007) Androgens and androgen receptors: a clinically neglected sector in breast cancer biology. J Surg Oncol 95: 437-439. (Pubitemid 46709384)
2. Higgins MJ, Wolff AC (2010) The androgen receptor in breast cancer: learning from the past. Breast Cancer Res Treat 124: 619-621.
3. Park S, Koo J, Park HS, Kim JH, Choi SY, et al. (2010) Expression of androgen receptors in primary breast cancer. Ann Oncol 21: 488-492.
4. Chang C, Lee SO, Yeh S, Chang TM (2013) Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver. Oncogene.
5. Hickey TE, Robinson JL, Carroll JS, Tilley WD (2012) Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene? Mol Endocrinol 26: 1252-1267.
6. Kotsopoulos J, Narod SA (2012) Androgens and breast cancer. Steroids 77: 1-9.
7. Nicolas Diaz-Chico B, German Rodriguez F, Gonzalez A, Ramirez R, Bilbao C, et al. (2007) Androgens and androgen receptors in breast cancer. J Steroid Biochem Mol Biol 105: 1-15.
8. Peters KM, Edwards SL, Nair SS, French JD, Bailey PJ, et al. (2012) Androgen receptor expression predicts breast cancer survival: the role of genetic and epigenetic events. BMC Cancer 12: 132.
9. Secreto G, Zumoff B (2012) Role of androgen excess in the development of estrogen receptor-positive and estrogen receptor-negative breast cancer. Anticancer Res 32: 3223-3228.
10. Ni M, Chen Y, Lim E, Wimberly H, Bailey ST, et al. (2011) Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell 20: 119-131.
11. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, Carey M, Agarwal R, et al. (2009) Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res 15: 2472-2478.
12. Yeh S, Hu YC, Wang PH, Xie C, Xu Q, et al. (2003) Abnormal mammary gland development and growth retardation in female mice and MCF7 breast cancer cells lacking androgen receptor. J Exp Med 198: 1899-1908. (Pubitemid 38032122)
13. Gucalp A, Traina TA (2010) Triple-negative breast cancer: role of the androgen receptor. Cancer J 16: 62-65.
14. Doane AS, Danso M, Lal P, Donaton M, Zhang L, et al. (2006) An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25: 3994-4008. (Pubitemid 43990755)
15. Birrell SN, Bentel JM, Hickey TE, Ricciardelli C, Weger MA, et al. (1995) Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol 52: 459-467.
16. Park S, Koo JS, Kim MS, Park HS, Lee JS, et al. (2011) Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. Ann Oncol 22: 1755-1762.
17. Sutton LM, Cao D, Sarode V, Molberg KH, Torgbe K, et al. (2012) Decreased androgen receptor expression is associated with distant metastases in patients with androgen receptor-expressing triple-negative breast carcinoma. Am J Clin Pathol 138: 511-516.
18. Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363: 1938-1948.
19. Cascione L, Gasparini P, Lovat F, Carasi S, Pulvirenti A, et al. (2013) Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer. PLoS One 8: e55910.
20. Guler G, Himmetoglu C, Jimenez RE, Geyer SM, Wang WP, et al. (2011) Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features. Breast Cancer Res Treat 129: 421-432.
21. McNamara KM, Yoda T, Takagi K, Miki Y, Suzuki T, et al. (2013) Androgen receptor in triple negative breast cancer. J Steroid Biochem Mol Biol 133: 66-76.
22. Nahleh Z (2008) Androgen receptor as a target for the treatment of hormone receptor-negative breast cancer: an unchartered territory. Future Oncol 4: 15-21.
23. Hudis CA, Gianni L (2011) Triple-negative breast cancer: an unmet medical need. Oncologist 16 Suppl 1: 1-11.
24. Thike AA, Yong-Zheng Chong L, Cheok PY, Li HH, Wai-Cheong Yip G, et al. (2013) Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer. Mod Pathol.
25. McNamara KM, Yoda T, Miki Y, Chanplakorn N, Wongwaisayawan S, et al. (2013) Androgenic pathway in triple negative invasive ductal tumors: its correlation with tumor cell proliferation. Cancer Sci 104: 639-646.
26. Tang D, Xu S, Zhang Q, Zhao W (2012) The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer. Med Oncol 29: 526-533.
27. He J, Peng R, Yuan Z, Wang S, Peng J, et al. (2012) Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol 29: 406-410.
28. McGhan LJ, McCullough AE, Protheroe CA, Dueck AC, Lee JJ, et al. (2013) Androgen Receptor-Positive Triple Negative Breast Cancer: A Unique Breast Cancer Subtype. Ann Surg Oncol.
29. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, et al. (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14: 1368-1376. (Pubitemid 351413917)
30. Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, et al. (2013) Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes. Clin Cancer Res 19: 5533-5540.
31. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, et al. (2007) Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9: 166-180.
32. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, et al. (2013) Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. Arch Pathol Lab Med.
33. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, et al. (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31: 3997-4013.
34. Montagna E, Maisonneuve P, Rotmensz N, Cancello G, Iorfida M, et al. (2013) Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome. Clin Breast Cancer 13: 31-39.
35. Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, et al. (2012) Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer 118: 5463-5472.
36. Guler G, Huebner K, Himmetoglu C, Jimenez RE, Costinean S, et al. (2009) Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2gamma expression levels correlate with basal phenotype in breast cancer. Cancer 115: 899-908.
37. Agoff SN, Swanson PE, Linden H, Hawes SE, Lawton TJ (2003) Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol 120: 725-731. (Pubitemid 37339680)
38. Network CGA (2012) Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70.
39. Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM, Bhargava R (2010) Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol 23: 205-212.
40. Kuenen-Boumeester V, Van der Kwast TH, Claassen CC, Look MP, Liem GS, et al. (1996) The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer 32A: 1560-1565. (Pubitemid 26279124)
41. Elsawaf Z, Sinn HP, Rom J, Bermejo JL, Schneeweiss A, et al. (2013) Biological subtypes of triple-negative breast cancer are associated with distinct morphological changes and clinical behaviour. Breast 22: 986-992.
42. Sutton LM, Han JS, Molberg KH, Sarode VR, Cao D, et al. (2010) Intratumoral expression level of epidermal growth factor receptor and cytokeratin 5/6 is significantly associated with nodal and distant metastases in patients with basal-like triple-negative breast carcinoma. Am J Clin Pathol 134: 782-787.
43. Dean JL, McClendon AK, Hickey TE, Butler LM, Tilley WD, et al. (2012) Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle 11: 2756-2761.
44. Tang LH, Contractor T, Clausen R, Klimstra DS, Du YC, et al. (2012) Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4/cdk6. Clin Cancer Res 18: 4612-4620.
45. Schonbrunn E, Betzi S, Alam R, Martin MP, Becker A, et al. (2013) Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases. J Med Chem 56: 3768-3782.
46. Dean JL, McClendon AK, Knudsen ES (2012) Modification of the DNA damage response by therapeutic CDK4/6 inhibition. J Biol Chem 287: 29075-29087.
47. McClendon AK, Dean JL, Rivadeneira DB, Yu JE, Reed CA, et al. (2012) CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy. Cell Cycle 11: 2747-2755.